SOLICITATION NOTICE
66 -- NuGEN Ovation Amplification System
- Notice Date
- 1/15/2010
- Notice Type
- Presolicitation
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- NHLBI-PB-(HL)-2010-057-DLM
- Archive Date
- 2/9/2010
- Point of Contact
- Dorothy Maxwell, Phone: 301-435-0352
- E-Mail Address
-
maxwelld@mail.nih.gov
(maxwelld@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation and a separate written solicitation will not be issued. This solicitation number is NHLBI-PB-(HL)-2010-057-DLM and is issued as a Request for Quotation (RFQ). The solicitation/contract will include all applicable provisions and clauses in effect through Federal Acquisition Circular 2005-38 (1/11/2010). The North American Industry Classification (NAICS) Code is 541711 and the business size standard is 500. This acquisition is being conducted using Simplified Acquisition Procedures in accordance with FAR Part 13. However, this solicitation is not set aside for small business. It is the intent of the National Institutes of Health (NIH) National Heart, Lung and Blood Institute to procure the following products from NuGEN Technologies, Inc., 821 Industrial Road, Unit A, San Carlos, California 94070. Items to be Purchased: 1. Item Number: 3300-A01, WT-Ovation™ Pico RNA Amplification System Automation, Quantity 21. 2. Item Number: 4200-A01, Encore™ Biotin Module Automation, Quantity 21. 3. Item Number: 2000-60, WT-Ovation™ Exon Module (60rx), Quantity 42. The sole source determination is based on the fact the National Institute of Health (NIH) is the nation’s medical research agency and the primary Federal agency conducting and supporting making medical discoveries that improve people’s health and save lives. The Framingham SABRe CVD Initiative Study under the National Heart, Lung, and Blood Institute (NHLBI) of NIH is conducting a study to identify the common factors or characteristics that contribute to Cardiovascular Disease (CVD) by following the development over a long period of time in a large group of participants who have not yet developed overt symptoms of CVD or suffered a heart attack or stroke. The study will expand research to include genomic biomarkers in CVD and will collaborate with other leading researchers across the country and world on various projects, such as, stroke and dementia, osteoporosis and arthritis and genetic patterns of common diseases. The collaborative study in biomarkers will analyze 7000 samples on Human Exon arrays to identify different expressed genes and associated alternative splicing events using the Affymetrix Platform. Specifically, the study will identify genes with altered expressions in heart, lung, and blood disorders and in a parallel study alternative splicing events during the disease process. The studies will be conducted in phases and the intent is to analyze gene expression in WBCs blood samples (n=2000) from Framingham Heart Study Offspring participants. Therefore, NHLBI is in need of NuGEN Technologies WT-Ovation Pico RNA Amplification System Automation to amplify 50 ng of total RNA from whole blood. The WT-Ovation Exon Module (60rx) will be used in preparation of labeled cDNA target to hybridize to Exon genechips. NuGEN Technologies is the only company that manufacturers these reagents. The Ovation® System family of products is covered by U.S. Patent Nos. 6,692,918, 6,251,639 and 6,946,251, and other issued and pending US and international patents. These are the only reagents that are suitable for the existing affymetrix platform operated in the core facility and the reagents have been validated in the core lab. In order to maintain a high standard of quality and reproducibility of experiments while increasing data output, the reagents manufactured by NuGEN is of critical importance. The Offeror must include a completed copy of the following provisions: 1) FAR Clause 52.212-1 Instructions to Offerors Commercial; 2) As stated in FAR Clause 52.212-2 (a), The Government will award a contract resulting from this solicitation to the responsible offeror whose offer conforming to the solicitation will be most advantageous to the Government, price and other factors considered. The following factors shall be used to evaluate offers: Technical Evaluation and Price. 3) FAR Clause 52.212-3, Offeror Representations and Certifications Commercial Items; 4) FAR Clause 52.212-4, Contract Terms and Conditions Required To Implement Statues or Executive Orders Commercial Items, Contract Terms and Conditions Commercial Items; and 5) FAR Clause 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders Commercial Items Deviation for Simplified Acquisitions. Only one responsible source and no other supplies or services will satisfy agency requirement. Interested parties may identify their interest and capability to respond to the requirement or submit proposals. This notice of intent is not a request for competitive quotations however; all responses received within five (5) days from the date of publication of this synopsis will be considered by the Government. A determination by the Government not to compete this proposed acquisition is based upon responses to this notice and is solely for the purpose of determining whether to conduct a competitive acquisition. The offeror must include in their quotation, the unit price, the list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. Note: In order to receive an award from the NHLBI contractors must have a valid registration in the Central Contractor Registration (CCR) www.ccr.gov. The clauses are available in full text at http://www.arnet.gov/far. Interested vendors capable of furnishing the government with the item specified in this synopsis should submit their quotation to the below address. Quotations will be due ten (10) calendar days from the publication date of this synopsis or by January 25, 2010, 7:30 a.m. Eastern Standard Time. The quotation must reference Solicitation number NHLBI-PB-(HL)-2010-057-DLM. All responsible sources may submit a quotation, which if timely received, shall be considered by the agency. Quotations must be submitted in writing to the National Heart, Lung and Blood Institute 6701 Rockledge Blvd., Room Suite 6100, Bethesda, Maryland 20892, Attention: Dorothy Maxwell, maxwelld@mail.nih.gov. Faxed copies are not accepted. Emails are accepted.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/NHLBI-PB-(HL)-2010-057-DLM/listing.html)
- Place of Performance
- Address: NIH, Bethesda, Maryland, 20892-7902, United States
- Zip Code: 20892-7902
- Zip Code: 20892-7902
- Record
- SN02043761-W 20100117/100115235726-ca71934c2a9085247a4428d772263528 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |